Deutsche Märkte geschlossen

TG Therapeutics, Inc. (TGTX)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
23,27-1,45 (-5,87%)
Ab 2:06PM EDT. Markt geöffnet.
Melden Sie sich an, um eine Nachricht zu posten.
  • B
    Biotech
    $TGTX conversation
    https://twitter.com/Biotech2050/status/1257899371238248448?s=19

    My price target remains $200+
    From my tweet last May:

    For the ultra $TGTX bulls trying to quantify bull case market cap:
    $5B CLL
    $2B NHL FL MZL
    $2B MS/ autoimmune diseases

    $9B x 3 = $27B ($246) vs $1.83B current MC.

    Do your own due diligence. Make sure you comprehend the upside potential. I am going for jackpot not breadcrumbs
  • B
    Biotech
    $TGTX conversation
    JPM Initiates coverage of TGTX with a price target of $38, overweight.

    Peak $TGTX sales per JPM
    $1.2B CLL
    $1.5B MS
    $0.45B MZL/FL

    At x3 peak sales of ~$3B = a potential market cap of $9B vs $3.1B current MC.

    Price target should be $75 and not the heavily discounted price of $38

    Also peak sales revenues are very conservative and do not include the multiple combo optionalies. Very promising!
  • B
    Biotech
    $TGTX conversation
    ISI $TGTX (OP, $65 PT)– 2Q results: ++ catalysts through YE; P3 UNITY CLL data, (U2 vs chlorambucil/Gazyva) an update on UNITY-NHL (umbra mono and various combos),P3 ubli for MS. TGTX is building its commercial team with hires from CELG & BMY, will launch umbra with ~40 reps then scale to 75 once U2 is approved for CLL. With its broad portfolio of targeted programs the company is also considering efforts in DLBCL, myelofibrosis and other indications. TGTX remains a top midcap pick as umbra combos remains v unappreciated
  • L
    Larry
    $TGTX conversation
    Fly On The Wall
    @FlyOnTheWallHQ
    Twist My Arm_TG THERAPEUTICS $TGTX CEO To Reveal Advanced Acquisition Talks Happening Now In NYC
  • Y
    Yum Yum
    $TGTX ok so a few things:

    1. Roche’s drug patent is being challenged again. So that could be a factor. Many US physicians aren’t too fond of biosimilars yet. Also, they reduce costs to the system not patients. Ultimately it won’t affect the usage of TGTX’s drug

    2. Short term manipulation before news announced at the end of the month. Manipulators know if they can get the stock on the cheap now, it’s going to rise significantly at the end of the month.

    There’s nothing to fret. PII MS data was 99% rate so it’s highly improbable that patients in PIII trial suddenly experienced a different therapeutic affect while on the drug

    It will be fine folks
  • T
    Terry
    $TGTX conversation
    WHO IS THIS GUY?

    Alex4 minutes ago
    TGTX digging itself a nice, big failure hole. It’s safe now to forget about $30 or even $28. Think about $25.

    Alex3 months ago
    $TGTX conversation
    TGTX doomed to flounder around in the 16.75-18.50 range for a while.
  • B
    Bill
    $TGTX conversation
    Strange I have to find this news today because I have holdings in $VSTM. Nothing alarming, but is a notable change within $TGTX!
    Verastem Oncology Announces Key Management Appointments
    Ms. Cavers joins Verastem from TG Therapeutics, Inc., a global biopharmaceutical company focused on the development of therapies in b-cell malignancies and autoimmune diseases, where she served as Vice President of Scientific Affairs. Her experience in developing and bringing novel therapies to market consists of several high-profile clinical programs and launches, including the drugs BOTOX, THALOMID, REVLIMID, VELCADE and KYPROLIS. She previously was Senior Director, Scientific Strategy and Communications at Onyx Therapeutics, U.S. Launch Lead for ixabepilone at Bristol-Myers Squibb Company, Senior Director, Global Strategic Marketing at Millennium Pharmaceuticals and Vice President, Marketing at Celgene Corporation. Ms. Cavers holds a B.S. in animal health science from the University of Arizona.
  • O
    Ouch
    $TGTX conversation
    Semodough tweet of the $100 TGTX bull case:....." ISI $TGTX
    $100 dollar BULL CASE: Ublituximab and Umbralisib emerge as leading therapies in CLL, MS, MZL & FL & PFIC with leading indications supporting >$4B in peak sales
    TGTX can be the next INCY, GMAB or SGEN – or even bigger given its differentiated portfolio and strategy"

    My response: Um...$4B "peak sales" would mean a LOT higher than $100 based on 5(X) multiple....
  • s
    stuckinnova
    TG Therapeutics, Inc.
    So for the many newcomers to this MB & asking for help in catching up on the latest TGTX info... here is a link to a recent Seeking Alpha article that provides a fairly good recap... Revisiting TG Therapeutics https://seekingalpha.com/article/4313035?source=ansh $TGTX
    TG Therapeutics’ stock is up significantly since it announced that TGR-1202 achieved its primary endpoint in a potentially registrational Phase 2b trial for fol
    TG Therapeutics’ stock is up significantly since it announced that TGR-1202 achieved its primary endpoint in a potentially registrational Phase 2b trial for fol
    seekingalpha.com
  • B
    Biotech
    $TGTX conversation
    For the ultra $TGTX bulls trying to quantify bull case market cap:
    $5B CLL
    $2B NHL FL MZL
    $2B MS/ autoimmune diseases

    $9B x 3 = $27B ($246) vs $2.2B current MC.

    Do your own due diligence. Make sure you comprehend the upside potential. I am going for jackpot not breadcrumbs
  • K
    Kim
    $SRPT conversation
    FromSY investing:
    Cantor 2020 #biotech outlook

    Top picks:
    - Large-cap: $VRTX $AMGN
    - Mid-cap: $SRPT $ALNY
    - Small-cap: $TGTX $ICPT $GBT $AGIO
    - Favorite binary: $MYOK
  • B
    Bill
    $TGTX conversation
    Still like the call options for $18 from last month report. $TGTX Investors need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 21, 2018 $18 Calls had some of the highest implied volatility of all equity options on 8/20/2018.
    https://www.zacks.com/stock/news/318606/is-the-options-market-predicting-a-spike-in-tg-therapeutics-tgtx-stock?cid=CS-YAHOO-FT-318606
    Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
    Investors in TG Therapeutics (TGTX) need to pay close attention to the stock based on moves in the options market lately.
    www.zacks.com
  • s
    stuckinnova
    TG Therapeutics, Inc.
    TG Therapeutics: Assessing The Investment Prospects Of A Potential Big Winner https://seekingalpha.com/article/4175330?source=ansh $TGTX, $ATRA
    TG Therapeutics is brewing two life-saving anti-cancer molecules. The combinations of ublituximab and umbralisib are ingeniously designed. Phase 3 (UNITY-CLL) t
    TG Therapeutics is brewing two life-saving anti-cancer molecules. The combinations of ublituximab and umbralisib are ingeniously designed. Phase 3 (UNITY-CLL) t
    seekingalpha.com
  • B
    Bill
    $TGTX conversation
    It`s pretty sad and sign of our times now that a Tweet 1 hour + ago would go viral and send $TGTX down into the shorts hands on NO concret news.Was the algo`s now the Tweets. Still have to trust your research and the fundamental while being watchful as the noise will overwhelm you. GLTA
  • F
    Faust
    JEFFERIES $TGTX data continue to suggest ubli has a similar to potentially better efficacy profile than Ocrevus, with more favorable dosing regimen.view ubli RMS as an under-appreciated,longterm shot on goal.key near-term event remains top-line ORR data from UNITY-CLL later in Q2. Laden $TGTX Positive Updated Ublituximab RMS Phase 2 Trial Data at AAN; Reiterate Buy, $32 PT . Suntrust $TGTX note that this is the first report we have seen of ARR with TG-1101, which is the primary endpoint in its two ongoing pivotal Phase III ULTIMATE I and II trials in RMS. In our view, the 24-week ARR compares highly favorably to those seen with Ocrevus
  • O
    Ouch
    $TGTX conversation
    Yeehaw!!!!

    Bill Millers tweet....

    ……………….

    Dr. Fowler said b/c of "Better Activity"(More rapid response, Much higher CR rates, and better tolerability, safety), he'd likely use $TGTX Umbralisib vs Ibrut. 60%/40%, & suggested maybe more frequently(if approved by PBMs, vs Ibrut :-)
  • B
    Bill
    $TGTX conversation
    The president 100 share walkdown by the algo`s when shorts/traders are missing during this holiday week can be disheartening but remember the number of phase 3 trials ongoing. Don't let trading be your guide with $TGTX, stick to the fundamentals for guidance.
  • L
    Larry
    $TGTX conversation
    SUPRISE!!!
    Updated Ublituximab Phase 2 data is MS is being presented today at AAN and now includes 6 month data for up to 48 patients! $TGTX
    Press Release: https://bit.ly/2Ho3TgD
    Poster: https://bit.ly/2qRuNDC
  • s
    stuckinnova
    TG Therapeutics, Inc.
    I'm guessing this guy missed yesterday's run up but still some interesting points in a good synopsis...
    TG Therapeutics At EHA 2018: Investors Unimpressed - Time To Get Focused https://seekingalpha.com/article/4182856?source=ansh $TGTX
    June 15th: the market was unimpressed by myelofibrosis and long-term safety readouts for umbralisib, likely because myelofibrosis is a small indication and we a
    June 15th: the market was unimpressed by myelofibrosis and long-term safety readouts for umbralisib, likely because myelofibrosis is a small indication and we a
    seekingalpha.com
  • B
    Blarney
    $TGTX conversation
    Bill Miller makes sense. Feuerstein is a hack for hire.

    $TGTX If Unity Data Bad,Little Reason to Delay Release-Better to Get It Out & Start to Spin-So Late Announce Most Probably Assoc'd w Getting Full12 Cycles Tx 4 All Pts,To Eliminate All PI3K Tox Concerns,Increase CRs & MRD-s, & Establish PFS Advantage&Assure Better Label
Mit Yahoo Nutzung stimmen Sie zu, dass Yahoo und Partner Cookies für Personalisierungs- und andere Zwecke nutzen